We are pleased to report that 2002 was a year of significant progress in establishing GlaxoSmithKline as one of the world’s leading pharmaceutical companies. We achieved …
We are pleased to report that 2002 was a year of significant progress in establishing GlaxoSmithKline as one of the world’s leading pharmaceutical companies.
GSK plc - Wikipedia
The case began in 2002, when GSK sent experts to fix problems cited by the FDA. The lead inspector recommended recalls of defective products, but they were not authorised; she was …
Corporate reports archive - GSK
Archive of Annual Reports and Corporate Responsibility Reports dating back to 2000.
A history of... GlaxoSmithKline - pharmaphorum
Sep 3, 2012 · By the end of 2002, GSK had secured 120 arrangements to supply these medicines to 50 of the world’s poorest country and in 2004, it shipped 33 million tablets of HIV treatment, …
About GlaxoSmithKline - Nature
Apr 17, 2003 · In 2002 GSK invested £2.6 billion in research and development at more than 20 sites in eight countries worldwide. GSK aspires to become the most productive R&D …
GlaxoSmithKline & malaria - Nature
In 2002, it is estimated that 40 countries will request more than 100 million treatments as part of this scheme, and GSK is committed to continuing this long-term programme.
GSK - 38 Year Stock Price History | GSK | MacroTrends
Historical daily share price chart and data for GSK since 1986 adjusted for splits and dividends. The latest closing stock price for GSK as of November 05, 2024 is 37.02. The all-time high …
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Nov 21, 2002 · We conducted two double-blind, randomized trials of a herpes simplex virus type 2 (HSV-2) glycoprotein-D–subunit vaccine with alum and 3- O -deacylated-monophosphoryl lipid …
an EHS strategy that builds on GSK business drivers and meets the fundamental requirements of environment, health and safety. In 2001 we put in place a framework of policies and standards …
- Some results have been removed